Clinical Trials & Surveys Corp. (C-TASC), a clinical trials solutions company, announced today that it has been selected to provide data management software and services to New York University School of Medicine (NYU), one of eight sites collecting data for a study being conducted by the Early Detection Research Network.
NEW YORK UNIVERSITY TAPS C-TASC FOR
CLINICAL STUDY DATA MANAGEMENT
Early Detection Research Network Study Aims to Improve
Early Diagnosis of Lung Cancer
Baltimore, Md. – (December 8, 2008)-Clinical Trials & Surveys Corp. (C-TASC), a clinical trials solutions company, announced today that it has been selected to provide data management software and services to New York University School of Medicine (NYU), one of eight sites collecting data for a study being conducted by the Early Detection Research Network. The purpose of the study is to identify biomarkers to serve as early detectors of lung cancer.
Under the three year contract, C-TASC will implement its StudyCTMSTM clinical trials management software solution to manage all EDRN study data collected and maintained at the New York University site. The software will be utilized to convert tens of thousands of existing data records into one universal format. Housing the data in a single format will make the accumulated results easier to read, compile, analyze and prepare for submission upon completion of the study. StudyCTMSTM will also be used for the collection and validation of all enrollment, follow up and specimen data for the 1,100 current study participants as well as all future participants.
C-TASC’s new Bio Repository Management System (BRMS), a fully integrated module of StudyCTMSTM, will also be deployed at NYU, enabling investigators to easily manage the processing, delivery, archival and allocation of all EDRN laboratory research specimens catalogued at the study site.
StudyCTMSTM is C-TASC’s proprietary Web-based data management solution that enables investigators to easily develop and manage clinical studies and deliver the accumulated data and metadata (labels, value labels, etc.) in an easy-to-read and FDA-acceptable format.
“C-TASC’s implementation of StudyCTMSTM at NYU is significant because it marks our first private software lease to a non-government supported researcher,” said Bruce Thompson, president of C-TASC. “Working with the EDRN will allow us to fine-tune the program’s array of features to ensure that we are providing clinical investigators with the optimum user experience to support their clinical trial work.”
About C-TASC
Based in Baltimore, Maryland, Clinical Trials & Surveys Corp. (C-TASC) is a clinical trials solutions company that supports best practices management of clinical trials, clinical cohort studies, case/control studies, clinical registries and laboratory studies. Founded in 1989, C-TASC provides clients with complete research management including medical and statistical study design, project management, performance monitoring and data quality control and analysis as well as support for study publication and presentations. C-TASC’s professional services group has a successful research history in cancer, cardiovascular disease, AIDS, pulmonary disease, Cystic Fibrosis, pharmaco-epidemiology and bio-repository establishment and coordination. For more information about C-TASC’s projects, products and services, please visit www.c-tasc.com <http://www.c-tasc.com/> .
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.